(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Figure out How to Improve Your Stream Voyage with Remarkable Trips and Exercises - 2Argentina reportedly delaying embassy move over Israeli company's oil project near Falklands
- 3Philippines evacuates 3,000 villagers after volcano activity raises alert level
- 4One spent $20 on candy. Another paid $700 for a custom costume. Here's how Halloween costs stacked up this year.
- 5Health insurance premiums rose nearly 3x the rate of worker earnings over the past 25 years
- Zelensky names spy chief to head presidential office after corruption row
- Tablets: Upgrade Your Understanding Experience
- Rediscovering Imagination in Adulthood: Individual Creative Excursions
- Virtual National Science Foundation internships aren’t just a pandemic stopgap – they can open up opportunities for more STEM students
- 15 Outrageous Cosplay Outfits That Will Blow You Away
- Discovery of ancient pleasure boat reveals Egypt's maritime history
- UAE-backed Yemeni Southern Transitional Council denies disbandment rumors
- Find Serenity: 10 Stunning Setting up camp Areas
- Novo Nordisk gears up for December Ozempic launch in India, sources say
